Extramammary Paget disease. Part I. epidemiology, pathogenesis, clinical features, and diagnosis.

Autor: Shah RR; Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey., Shah K; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York., Wilson BN; Department of Pediatrics, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts., Tchack M; Department of Dermatology, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey., Busam KJ; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Moy A; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Leitao MM; Department of Gynecology, Memorial Sloan Kettering Cancer Center, New York, New York., Cordova M; Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York., Neumann NM; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York., Smogorzewski J; Department of Medicine, Harbor-UCLA Medical Center, Los Angeles, California., Nguyen KA; Department of Dermatology, West Virginia University, Morgantown, West Virginia., Hosein S; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York., Dafinone M; Department of Dermatology, Reno School of Medicine, University of Nevada, Reno, Nevada., Schwartz RA; Department of Dermatology, Rutgers New Jersey Medical School, Newark, New Jersey., Rossi A; Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. Electronic address: rossia@mskcc.org.
Jazyk: angličtina
Zdroj: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2024 Sep; Vol. 91 (3), pp. 409-418. Date of Electronic Publication: 2024 May 02.
DOI: 10.1016/j.jaad.2023.07.1051
Abstrakt: Extramammary Paget disease (EMPD) is a rare skin cancer of apocrine-rich skin that mimics common inflammatory and infectious dermatoses, leading to delays in diagnosis and increased patient morbidity. Better clinical recognition of this entity, multidisciplinary patient assessment, and deeper understanding of the underlying pathophysiology are essential to improve patient care and disease outcomes. It is important to distinguish primary intraepithelial/micro-invasive EMPD from invasive EMPD or cases with adenocarcinoma arising within EMPD. This 2-part continuing medical education series provides a complete picture of EMPD. Part 1 of this continuing medical education series reviews the epidemiology, oncogenesis, clinical and histopathologic presentation, workup, and prognosis of this rare cancer.
Competing Interests: Conflict of interest Anthony Rossi: Dr Rossi has no relevant conflicts of interest related to this manuscript. He also served on advisory board, as a consultant, or given educational presentations for: Almirall; Allergan, Inc; Galderma Inc; Evolus Inc; Elekta; Biofrontera, Quantia; Merz Inc; Dynamed; Skinuvia; Perf-Action; Cutera; and LAM therapeutics. Equity in DAR companies.
(Copyright © 2024 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: